Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)

Starting soon · Phase 1/Phase 2

Conditions studied: Resectable Hepatocellular Carcinoma

In brief

The purpose of this phase Ib/II multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC

Key facts

Study ID: NCT07714317
Run by: Shanghai Zhongshan Hospital
People needed: 90
Starts: 2026-07-20
Expected to finish: 2030-05-31
Last updated by the study team: 2026-07-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Written informed consent shall be obtained prior to any trial-related procedures.
Male or female patients aged ≥18 years and ≤75 years.
Initial resectable hepatocellular carcinoma (HCC) confirmed by imaging, pathology or cytology.
No macrovascular tumor thrombus or extrahepatic metastasis detected on imaging examinations.
Single intrahepatic tumor >5 cm in diameter, or 2-3 intrahepatic tumors with no restriction on tumor diameter (corresponding to CNLC stage Ib-IIa of primary liver cancer in China).
The maximum tumor diameter < 8 cm.
Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
Child-Pugh Class A liver function.
No prior systemic therapy or locoregional therapy for HCC; patients with recurrence ≥2 years after previous curative surgical resection or ablation are eligible for enrollment.
At least one measurable lesion per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Adequate organ function.

You may not qualify if…

Histologically or cytologically confirmed tumors containing components of fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, or other mixed subtypes.
History of hepatic encephalopathy or prior liver transplantation.
Currently participating in an interventional clinical trial, or received any investigational medicinal product or investigational device within 4 weeks prior to the first study drug administration.
Prior receipt of any of the following therapies: anti-PD-1, anti-PD-L1, anti-PD-L2 agents, or agents targeting other T-cell co-stimulatory or co-inhibitory receptors (including but not limited to CTLA-4, OX-40, CD137).
Received systemic therapy with Chinese patent medicines with anti-tumor indications or immunomodulatory agents (including thymopeptides, interferons, interleukins; excluding local intrapleural administration for controlling pleural effusion) within 2 weeks prior to the first study drug administration.
History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, immunosuppressants) within 2 years before the first study drug administration. Replacement therapies (e.g., thyroxine, insulin, physiologic corticosteroids for adrenal or pituitary insufficiency) shall not be regarded as systemic treatment.
Receiving systemic corticosteroid therapy (excluding intranasal, inhaled, or other locally administered corticosteroids) or any other form of immunosuppressive therapy within 7 days prior to the first study drug administration.
Note: Physiologic doses of corticosteroids (≤10 mg prednisone equivalent per day) are permitted.
Known history of allogeneic solid organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
Known hypersensitivity to any study drug used in this trial.
Have not fully recovered from toxicities and/or complications induced by any prior intervention before study treatment initiation.
Known history of human immunodeficiency virus (HIV) infection.
Untreated active hepatitis B virus (HBV) infection.
Subjects with active hepatitis C virus (HCV) infection.
Received any live vaccine within 30 days prior to the first study drug administration (Day 1 of Cycle 1).
Pregnant or lactating women.
Presence of any severe or uncontrolled systemic disease.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.